OrganoTherapeutics and mo:re join forces on a pipeline for organoid culture automation

At OrganoTherapeutics, we produce midbrain organoids on a large scale for simultaneous testing of numerous therapeutics and conditions. With the capability to culture hundreds, and even thousands, of organoids concurrently, speed and efficiency are crucial.

We are thrilled to share news of our latest collaboration with the innovative German company, mo:re. Together, we're implementing an advanced automation pipeline, integrating mo:re's cutting-edge automation and AI-assisted ed robotic and software platform with our organoids. This partnership promises to enhance our research capabilities and accelerate breakthroughs in therapeutic development.

Previous
Previous

𝐖𝐞𝐥𝐜𝐨𝐦𝐞 𝐭𝐨 𝐎𝐫𝐠𝐚𝐧𝐨𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬' 𝐧𝐞𝐰 𝐥𝐚𝐛 𝐬𝐩𝐚𝐜𝐞

Next
Next

UAB and OrganoTherapeutics collaborate on PD therapeutics